PNEUMONIX ATTENDS ASPIRE INVESTOR READINESS PROGRAM THROUGH VENTUREWELL

shash683
Mar 15, 2019
1 min read

PneumoNIX was selected as 1 of 15 MedTech start-ups to attend VentureWell’s investor readiness program. The program ensures the companies have a solidified go-to-market plan with planned milestones and a comprehensive due diligence deal room package. Furthermore, PneumoNIX secured partnerships to help with product launch and market adoption.

Recent Posts

See All

PNEUMONIX MEDICAL RECEIVES NSF SBIR PHASE II GRANT

PneumoNIX has received follow-on Phase II grant from the NSF SBIR to continue the development of their proprietary technology.

PNEUMONIX MEDICAL RECEIVES NSF SBIR PHASE I GRANT

PneumoNIX Medical, a Baltimore-based medtech company focused on preventing complications associated with soft tissue biopsies, announced...

PNEUMONIX MEDICAL ENDORSED BY JOHNS HOPKINS LUNG CANCER SCREENING INITIATIVE

PneumoNIX Medical was selected to present to Johns Hopkins Hospital, Maryland Department of Commerce and Technology Development...

Comments